MCID: TST026
MIFTS: 43

Testicular Germ Cell Cancer

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Testicular Germ Cell Cancer

MalaCards integrated aliases for Testicular Germ Cell Cancer:

Name: Testicular Germ Cell Cancer 12 15
Testicular Germ Cell Tumor 45 74
Testicular Malignant Germ Cell Tumor 74
Testicular Germ Cell Neoplasm 12
Germ Cell Tumor of Testis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5557
MeSH 45 C563236
NCIt 51 C8591

Summaries for Testicular Germ Cell Cancer

Disease Ontology : 12 A testicular cancer that has material basis in germ cells.

MalaCards based summary : Testicular Germ Cell Cancer, also known as testicular germ cell tumor, is related to testicular germ cell tumor and germ cell cancer. An important gene associated with Testicular Germ Cell Cancer is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Coregulation of Androgen receptor activity and Ovarian Infertility Genes. The drugs Cisplatin and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and testis, and related phenotype is limbs/digits/tail.

Related Diseases for Testicular Germ Cell Cancer

Diseases in the Testicular Germ Cell Cancer family:

Testicular Malignant Germ Cell Cancer

Diseases related to Testicular Germ Cell Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 96)
# Related Disease Score Top Affiliating Genes
1 testicular germ cell tumor 34.4 AR DMRT1 KITLG
2 germ cell cancer 30.9 AR DMRT1 ESR2 KITLG LHCGR
3 prostate cancer 28.5 AR ESR2 MEG3 SPRY4-IT1 XIST
4 testicular germ cell tumor 1 12.7
5 pediatric testicular germ cell tumor 12.5
6 testicular germ cell tumor non-seminomatous 12.4
7 testicular malignant germ cell cancer 11.4
8 pigmented villonodular synovitis 11.4
9 testicular seminoma 11.3
10 germ cells tumors 11.1
11 embryonal carcinoma 10.4
12 testicular microlithiasis 10.4
13 teratoma 10.3
14 choriocarcinoma 10.3
15 rhabdomyosarcoma 10.3
16 postmenopausal atrophic vaginitis 10.2 AR ESR2
17 vaginitis 10.2 AR ESR2
18 transsexualism 10.2 AR ESR2
19 nonseminomatous germ cell tumor 10.2
20 gender identity disorder 10.2 AR ESR2
21 in situ carcinoma 10.2
22 prostatic hyperplasia, benign 10.2 AR ESR2
23 oligospermia 10.2 AR KITLG
24 mixed germ cell tumor 10.1
25 stroke, ischemic 10.1
26 dermatomyositis 10.1
27 down syndrome 10.1
28 wilms tumor 5 10.1
29 wilms tumor 6 10.1
30 angiosarcoma 10.1
31 azoospermia 10.1
32 endodermal sinus tumor 10.1
33 mature teratoma 10.1
34 hydrocele 10.1
35 pseudovaginal perineoscrotal hypospadias 10.1 AR LHCGR
36 male reproductive organ cancer 10.0 AR ESR2
37 pseudohermaphroditism 10.0 AR LHCGR
38 von hippel-lindau syndrome 10.0
39 neuroblastoma 10.0
40 intussusception 10.0
41 body mass index quantitative trait locus 1 10.0
42 bone mineral density quantitative trait locus 3 10.0
43 thrombocytopenia 10.0
44 ulcerative colitis 10.0
45 colitis 10.0
46 hypospadias 10.0
47 estrogen excess 10.0
48 hypogonadism 10.0
49 testicular cancer 10.0
50 seminoma 10.0

Graphical network of the top 20 diseases related to Testicular Germ Cell Cancer:



Diseases related to Testicular Germ Cell Cancer

Symptoms & Phenotypes for Testicular Germ Cell Cancer

MGI Mouse Phenotypes related to Testicular Germ Cell Cancer:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 limbs/digits/tail MP:0005371 8.92 AR BLMH ESR2 KITLG

Drugs & Therapeutics for Testicular Germ Cell Cancer

Drugs for Testicular Germ Cell Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 313)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
2
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
3
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
4
Testosterone enanthate Approved Phase 4,Phase 2,Phase 3 315-37-7 9416
5
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2,Phase 3 5949-44-0
6
Testosterone Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3 58-22-0, 481-30-1 6013 10204
7
Methyltestosterone Approved Phase 4,Phase 2,Phase 3 58-18-4 6010
8
Docetaxel Approved, Investigational Phase 4,Phase 2 114977-28-5 148124
9
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3 50-28-2 5757
10
Polyestradiol phosphate Approved Phase 4,Phase 3 28014-46-2
11 Immunologic Factors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
12 Adjuvants, Immunologic Phase 4,Phase 3,Phase 1,Phase 2
13 interferons Phase 4,Phase 1,Phase 2
14 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Not Applicable
15 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
18 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Interferon Inducers Phase 4,Phase 1,Phase 2
20 Testosterone 17 beta-cypionate Phase 4,Phase 2,Phase 3
21 Anabolic Agents Phase 4,Phase 2,Phase 3
22 Androgens Phase 4,Phase 2,Phase 3
23 tyrosine Phase 4
24 Follicle Stimulating Hormone Phase 4
25 Estradiol 3-benzoate Phase 4,Phase 3
26 Estradiol 17 beta-cypionate Phase 4,Phase 3
27
Ifosfamide Approved Phase 3,Phase 1,Phase 2 3778-73-2 3690
28
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
29
Vinblastine Approved Phase 3 865-21-4 13342 241903
30
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
31
Granisetron Approved, Investigational Phase 3,Not Applicable 109889-09-0 3510
32
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
33
Mechlorethamine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 51-75-2 4033
34
Bleomycin Approved, Investigational Phase 3,Phase 2,Not Applicable 11056-06-7 5360373
35
Oxaliplatin Approved, Investigational Phase 3,Phase 2 61825-94-3 6857599 5310940 9887054 43805
36
Lenograstim Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 135968-09-1
37
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 1177-87-3
38
Mesna Approved, Investigational Phase 3,Phase 1,Phase 2 3375-50-6 598
39
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 50-02-2 5743
40
Ofloxacin Approved Phase 3 82419-36-1 4583
41
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
42
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
43
Captopril Approved Phase 3 62571-86-2 44093
44
Ribavirin Approved Phase 3 36791-04-5 37542
45
Palivizumab Approved, Investigational Phase 3 188039-54-5
46
Itraconazole Approved, Investigational Phase 3,Not Applicable 84625-61-6 55283
47
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
48
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
49
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 2826718 468682
50
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965

Interventional clinical trials:

(show top 50) (show all 294)
# Name Status NCT ID Phase Drugs
1 Taste, Smell and Chemotherapy (TASTY) Completed NCT01641172 Phase 4
2 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
3 Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters Recruiting NCT03203681 Phase 4 NATESTO® (4.5% nasal testosterone) Nasal Gel
4 Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
5 Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors Unknown status NCT00002566 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;ifosfamide;vinblastine sulfate
6 Magnetic Resonance Imaging and Computed Tomography in Patients With Stage I Seminoma of the Testicle Unknown status NCT00589537 Phase 3
7 Lerisetron Compared With Granisetron in Preventing Nausea and Vomiting in Men Being Treated With Radiation Therapy for Stage I Seminoma Unknown status NCT00004219 Phase 3 granisetron hydrochloride;lerisetron
8 Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors Unknown status NCT00104676 Phase 3 cisplatin;etoposide;ifosfamide;oxaliplatin;paclitaxel
9 Combination Chemotherapy in Treating Men With Germ Cell Cancer Unknown status NCT00003643 Phase 2, Phase 3 cisplatin;etoposide;paclitaxel
10 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
11 Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Unknown status NCT00274950 Phase 3 carboplatin;cisplatin;etoposide;ifosfamide;vinblastine sulfate
12 Radiation Therapy Compared With Chemotherapy in Treating Patients With Stage I Testicular Cancer Completed NCT00003014 Phase 3 carboplatin
13 Bleomycin, Etoposide, and Cisplatin in Treating Patients With Metastatic Germ Cell Cancer of the Testicles Completed NCT00324298 Phase 3 cisplatin;etoposide
14 Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors Completed NCT00002596 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide
15 Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors Completed NCT00053352 Phase 3 cisplatin;etoposide
16 Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer Completed NCT00003941 Phase 3 cisplatin;etoposide;ifosfamide
17 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
18 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
19 Androgen for Leydig Cell Proliferation Completed NCT01206270 Phase 2, Phase 3 Testosterone undecanoate;Castor Oil
20 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
21 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
22 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
23 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
24 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
25 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
26 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
27 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
28 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
29 Study of Testosterone vs Placebo in Testicular Cancer Survivors Recruiting NCT02991209 Phase 2, Phase 3 Testosterone;Placebos
30 Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer Recruiting NCT02341989 Phase 3 Bleomycin Etoposide and Cisplatin;Carboplatin
31 Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours Recruiting NCT02582697 Phase 3 Bleomycin (active name: Bleomycin Sulfate);Etoposide;Cisplatin;Pegylated G-CSF (Pegfilgrastim);Filgrastim
32 Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors Recruiting NCT02375204 Phase 3 paclitaxel;ifosfamide;cisplatin;pegylated G-CSF;G-CSF;carboplatin;etoposide phosphate
33 Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours Active, not recruiting NCT01726374 Phase 3 BEP(500)
34 Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate Active, not recruiting NCT01444820 Phase 3
35 Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors Terminated NCT00072215 Phase 3 cisplatin;ifosfamide;paclitaxel;vinblastine
36 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
37 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
38 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
39 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Unknown status NCT01883518 Phase 1, Phase 2
40 Effectiveness of an Individualized Program of Muscular Strength and Endurance Program for Improving Germ Cell Cancer Unknown status NCT02433197 Phase 1, Phase 2
41 Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy Unknown status NCT00772694 Phase 2 sorafenib
42 Peptide Vaccination in Treating Patients With Esophageal Cancer (STF-II) Unknown status NCT01267578 Phase 2
43 A Study With Peptide Vaccination in Treating Patients With Esophageal Cancer Unknown status NCT00995358 Phase 2
44 Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer Unknown status NCT01592617 Phase 2 S-488410
45 Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation Unknown status NCT01758367 Phase 1, Phase 2 Deciatbine(DAC)
46 Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors Unknown status NCT01743482 Phase 2 Pazopanib
47 Promotora-based Latino Family CVD Risk Reduction Unknown status NCT01714271 Phase 2
48 Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors Unknown status NCT00551122 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;ifosfamide;paclitaxel
49 Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors Unknown status NCT00127049 Phase 2 gemcitabine, ifosfamide, cisplatin, G-CSF
50 High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy Unknown status NCT01172912 Phase 2 carboplatin;cisplatin;dexamethasone;etoposide;ifosfamide

Search NIH Clinical Center for Testicular Germ Cell Cancer

Cochrane evidence based reviews: testicular germ cell tumor

Genetic Tests for Testicular Germ Cell Cancer

Anatomical Context for Testicular Germ Cell Cancer

MalaCards organs/tissues related to Testicular Germ Cell Cancer:

42
Bone, Bone Marrow, Testis, T Cells, Brain, Lymph Node, Ovary

Publications for Testicular Germ Cell Cancer

Articles related to Testicular Germ Cell Cancer:

(show top 50) (show all 139)
# Title Authors Year
1
Re: MicroRNA-371a-3p as Informative Biomarker for the Follow-up of Testicular Germ Cell Cancer Patients. ( 30634340 )
2019
2
Molecular heterogeneity and early metastatic clone selection in testicular germ cell cancer development. ( 30739914 )
2019
3
Re: Risk of Solid Cancer after Treatment of Testicular Germ Cell Cancer in the Platinum Era. ( 30759676 )
2019
4
Current pharmacotherapy for testicular germ cell cancer. ( 30849243 )
2019
5
Association between male pattern baldness and testicular germ cell tumor: a meta-analysis. ( 30634927 )
2019
6
Spontaneous regression as a 'burned-out' non-seminomatous testicular germ cell tumor: a case report and literature review. ( 30647899 )
2019
7
Testicular germ cell tumor: a comprehensive review. ( 30671589 )
2019
8
Association between androgen receptor gene polymorphisms and testicular germ cell tumor: A systematic review and meta-analysis. ( 30900623 )
2019
9
Complex Polygenic Nature of Testicular Germ Cell Cancer Suggests Multifactorial Aetiology. ( 29530636 )
2018
10
Is the FSHR 2039A>G variant associated with susceptibility to testicular germ cell cancer? ( 29179257 )
2018
11
CK7, inhibin, and p63 in testicular germ cell tumor: superior markers of Choriocarcinoma compared to β-hCG. ( 30359635 )
2018
12
Mature Cystic Teratoma of the Lung With a Somatic-Like Malignant Component in a Patient With Testicular Germ-Cell Tumor. ( 30041955 )
2018
13
Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era. ( 29989856 )
2018
14
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. ( 30113631 )
2018
15
Seminoma component of mixed testicular germ cell tumor shows a higher incidence of loss of heterozygosity than pure-type seminoma. ( 30266250 )
2018
16
Re: Identification of 19 New Risk Loci and Potential Regulatory Mechanisms Influencing Susceptibility to Testicular Germ Cell Tumor. ( 30227584 )
2018
17
A miR-125b/CSF1-CX3CL1/tumor-associated macrophage recruitment axis controls testicular germ cell tumor growth. ( 30237497 )
2018
18
MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients. ( 30321995 )
2018
19
Clinicopathological Significance and Antitumor Effect of MPHOSPH1 in Testicular Germ Cell Tumor. ( 30519350 )
2018
20
microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients. ( 28612337 )
2017
21
Cisplatin-related Cerebral Infarction in Testicular Germ Cell Cancer: Short Report of Three Cases and P in testicular germ cell cancer: Short report of three cases and pathomechanism. ( 27923208 )
2017
22
Risk of low bone mineral density in testicular germ cell cancer survivors: association with hypogonadism and treatment modality. ( 28591464 )
2017
23
Animacroxam, a novel dual-mode compound targeting histone deacetylases and cytoskeletal integrity of testicular germ cell cancer cells. ( 28838999 )
2017
24
A Brief Review of the Link between Environment and Male Reproductive Health: Lessons from Studies of Testicular Germ Cell Cancer. ( 26871895 )
2016
25
Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review. ( 27821802 )
2016
26
Androgen receptor gene CAG and GGN repeat lengths as predictors of recovery of spermatogenesis following testicular germ cell cancer treatment. ( 27873769 )
2016
27
Increasing international efforts to understand and conquer testicular germ cell cancer. ( 25711179 )
2015
28
Treatment-related cardiovascular late effects and exercise training countermeasures in testicular germ cell cancer survivorship. ( 25751759 )
2015
29
Re: Yvonne Vergouwe, Ewout W. Steyerberg, Richard S. Foster, et al. Predicting Retroperitoneal Histology in Postchemotherapy Testicular Germ Cell Cancer: A Model Update and Multicentre Validation with More Than 1000 Patients. Eur Urol 2007;51:424-32. ( 26726125 )
2015
30
Reply to Nahid Punjani, Nicholas Power, Eric Winquist's Letter to the Editor re: Yvonne Vergouwe, Ewout W. Steyerberg, Richard S. Foster, et al. Predicting Retroperitoneal Histology in Postchemotherapy Testicular Germ Cell Cancer: A Model Update and Multicentre Validation with More Than 1000 Patients. Eur Urol 2007;51:424-32. ( 26726124 )
2015
31
Muscle-building supplement use and increased risk of testicular germ cell cancer in men from Connecticut and Massachusetts. ( 25826226 )
2015
32
Surveillance policy for Japanese patients with stage I testicular germ cell cancer in the multi-detector computed tomography era. ( 25893862 )
2015
33
Salvage chemotherapy with gemcitabine plus oxaliplatin for patients with testicular germ cell cancer. ( 24647526 )
2014
34
Trends in testicular germ cell cancer incidence in Eastern Croatia. ( 24496357 )
2014
35
An oncofetal and developmental perspective on testicular germ cell cancer. ( 25066859 )
2014
36
Changes in epidemiologic features of testicular germ cell cancer: Age at diagnosis and relative frequency of seminoma are constantly and significantly increasing. ( 23395239 )
2014
37
Circulating Serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as Biomarkers in Patients with Testicular Germ Cell Cancer. ( 25046619 )
2014
38
Nodal, pulmonary and pleural gliomatosis in a 42-year-old-male with non-seminomatous testicular germ cell cancer. ( 24444134 )
2014
39
Thrombocytopenia following high-dose chemotherapy with carboplatin, etoposide and thiotepa in patients with testicular germ cell cancer. ( 23260006 )
2013
40
Expression analysis of RNA-binding motif gene on Y chromosome (RBMY) protein isoforms in testis tissue and a testicular germ cell cancer-derived cell line (NT2). ( 23567846 )
2013
41
Just another brick in the wall: unravelling the epigenetic mechanism underlying tumour initiation of testicular germ cell cancer. ( 24292446 )
2013
42
Association between polymorphisms in the aryl hydrocarbon receptor repressor gene and disseminated testicular germ cell cancer. ( 23420531 )
2013
43
Re: Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer. ( 24120784 )
2013
44
Sperm concentration, testicular volume and age predict risk of carcinoma in situ in contralateral testis of men with testicular germ cell cancer. ( 23770148 )
2013
45
Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model. ( 23098692 )
2013
46
Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principle. ( 24012110 )
2013
47
Changing epidemiologic features of testicular germ cell cancer in Germany: corroboration at population level. ( 24035419 )
2013
48
Genome-wide assessment of the association of rare and common copy number variations to testicular germ cell cancer. ( 23372565 )
2013
49
Replication of genetic susceptibility loci for testicular germ cell cancer in the Croatian population. ( 22745383 )
2012
50
Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer. ( 23169338 )
2012

Variations for Testicular Germ Cell Cancer

Expression for Testicular Germ Cell Cancer

Search GEO for disease gene expression data for Testicular Germ Cell Cancer.

Pathways for Testicular Germ Cell Cancer

Pathways related to Testicular Germ Cell Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.71 AR PIAS1
2 10.13 ESR2 LHCGR

GO Terms for Testicular Germ Cell Cancer

Biological processes related to Testicular Germ Cell Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.56 AR DMRT1 ESR2 PIAS1
2 androgen receptor signaling pathway GO:0030521 9.16 AR PIAS1
3 sex differentiation GO:0007548 8.96 AR DMRT1
4 male gonad development GO:0008584 8.92 AR DMRT1 KITLG LHCGR

Molecular functions related to Testicular Germ Cell Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 steroid hormone receptor activity GO:0003707 9.16 AR ESR2
2 nuclear receptor activity GO:0004879 8.96 AR ESR2
3 steroid binding GO:0005496 8.62 AR ESR2

Sources for Testicular Germ Cell Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....